- Title
- Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: First disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
- Creators
- Toon Van Gorp - Division of Gynaecological Oncology, University Hospital Leuven and KU Leuven, Leuven Cancer Institute, Leuven, BelgiumIgnace Vergote - Division of Gynaecological Oncology, University Hospital Leuven and KU Leuven, Leuven Cancer Institute, Leuven, BelgiumLeslie Randall - Virginia Commonwealth UniversityJacqueline Tromp - Department of Medical Oncology, Amsterdam University Medical Center, Amsterdam, the NetherlandsDomenica Lorusso - Mylan (Switzerland)David Cibula - Charles UniversityAna Oaknin - Vall d'Hebron Institute of Oncologyhannelore denys - Ghent University HospitalSharad Ghamande - Augusta UniversityIngrid Boere - Erasmus MC Cancer InstituteBradley Monk - Florida Cancer Specialists and Research Institute, West Palm Beach, FL, United Stateset al.
- Publication Details
- Gynecologic oncology, Vol.208, pp.S37-S38
- Publisher
- Elsevier Inc
- Identifiers
- 991006271510602656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: First disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
Gynecologic oncology, Vol.208, pp.S37-S38
05/2026
Metrics
1 Record Views